Skip to main content
MRK logo

MRK · Merck & Co., Inc.

Track MRK — free
$132.06 -5.72 (-4.15%)
Market Cap
$327.41B
Shares
2.47B
Volume · Nov 19 13.43M Avg daily vol (3M) 9.92M

Price & Indicators

Close$132.81 Open$139.17 Day$131.36–139.17 52W close$94.97–156.45 Avg vol 30d9.8M Short int26.6M · 1.1% of shares · 2.4d Short vol43% Last earningsOct 29, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 2, 2027 Scheduled · in 11 wks

Latest documents

2026
Nov 19
Investor event
FDA wants mature U.S. data in trials after Harmony CRL

Merck said the FDA wants trial data that include U.S. patients, after the Harmony CRL. Executives said the maturity of U.S. data matters more than the percentage of U.S. patients. They also described MK1084 as well tolerated.

5 source passages
So first of all, the U.S. is pretty clear that they want data that also includes U.S. patients, period. But we did get the Harmony CRL recently. It's not the percentage, it's the maturity that's important, and that really has made a difference for us Calderasiv, or MK1084, is exactly that. It's really well tolerated. Open the document at this passage
Nov 18
Current report 8-K Events of Nov 16
Glocer to retire from Merck board in May 2027; Baker named lead director

Thomas H. Glocer notified the Board he intends to retire at the 2027 Annual Meeting of Shareholders, with no disagreement with the Company. Douglas M. Baker, Jr. will become independent lead director effective Jan. 1, 2027, succeeding Mr. Glocer.

Director or officer change, or executive pay
3 source passages
Thomas H. Glocer gave notice to Merck & Co., Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”) as of the Company’s 2027 Annual Meeting of Shareholders. The independent members of the Board have appointed Douglas M. Baker, Jr., as independent lead director, effective Jan. 1, 2027, succeeding Mr. Glocer in the role. Mr. Glocer’s retirement from the Board is not due to any disagreement with the Company with respect to any matter relating to the Company’s operations, policies or practices. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cidara acquisition carried $9.0 billion R&D charge

Merck recorded a $9.0 billion R&D charge after acquiring Cidara Therapeutics, Inc. for $9.2 billion in May 2026. Worldwide sales increased 5% to $18.1 billion in the third quarter of 2026 amid pricing pressure.

Revenue $18.09B ▲ 4.7% Net income $5.07B ▼ 12.4% Diluted EPS $2.04 ▼ 12.1%
Read from the MD&A section
3 source passages
In May 2026, Merck acquired Cidara Therapeutics, Inc. (Cidara), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for $9.2 billion (including $570 million of payments to settle share-based equity awards of which $406 million related to unvested equity awards). Merck recorded a charge of $9.0 billion to Research and development expenses (which primarily represented acquired IPR&D with no alternative future use), or $3.62 per share, in the first nine months of 2026, as well as net assets of $332 million. Worldwide sales were $18.1 billion and $51.0 billion in the third quarter and first nine months of 2026, respectively, representing increases of 5% compared with the same periods of 2025, primarily driven by growth in the oncology and cardiometabolic, respiratory and specialty franchises, as well as animal health, partially offset by a decline in the vaccines and infectious diseases franchise. Open the document at this passage
Oct 29
Current report 8-K
Third-Quarter Sales Reach $18,085 Million, Up 5%; GAAP EPS $2.04

Merck reported third-quarter 2026 sales of $18,085 million, up 5%, with GAAP EPS of $2.04 and non-GAAP EPS of $2.49, both including a one-time $0.12 per share charge tied to a SciBrunch license agreement. Full-year 2026 sales are now expected between $66.8 billion and $67.3 billion. Non-GAAP EPS guidance was narrowed and raised to between $2.77 and $2.82.

Financial results Read from the first part of this long document
6 source passages
Total Sales | 18,085 | 17,276 | | 5% GAAP EPS was $2.04 for the third quarter of 2026 Non-GAAP EPS was $2.49 for the third quarter of 2026 Both GAAP and non-GAAP EPS in the third quarter of 2026 include a one-time charge of $0.12 per share related to a global license agreement with SciBrunch Therapeutics Co., Ltd. (SciBrunch). Now Expects Sales To Be Between $66.8 Billion and $67.3 Billion Narrows and Raises Expected Non-GAAP EPS Range To Be Between $2.77 and $2.82 Open the document at this passage
Oct 13
Current report 8-K Events of Oct 9
Director or officer change, or executive pay

Merck & Co., Inc. elected Paul J. Diaz to its Board of Directors effective November 1, 2026, appointed him to the Audit Committee and Research Committee, and expanded the Board to 14 members. Diaz will stand for shareholder election in May 2027.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$67.38B
Trailing 12 months
Net income (TTM)
$2.45B
Trailing 12 months
Revenue growth YoY
+4.7%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
142.0
Trailing earnings · reciprocal yield 0.7%
FCF yield
4.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$44.13B
Latest balance sheet
Dividend yield
2.5%
Trailing 12 months
Shares change YoY
-0.8%
Year over year · fewer shares
Price change (1Y)
+42.9%
Trailing year
Short interest
1.1%
Latest settlement · 2.4 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26

TL;DR. Second-quarter sales rose 5% to $16.6 billion and full-year revenue guidance was raised to $66.3 to $67.3 billion, with FDA approval of Lipfendra. Non-GAAP results were a $0.13 per share loss on the $2.31 per share Terns charge, and Keytruda growth is expected to moderate.

Bullish
  • + Total worldwide sales rose 5% to $16.6 billion, or 4% excluding foreign exchange.
  • + Full-year 2026 revenue guidance was raised and narrowed to $66.3 to $67.3 billion.
  • + WINREVAIR sales rose 75% to $588 million on continued demand in pulmonary arterial hypertension.
  • + Keytruda family sales rose 4% to $8.4 billion, driven by earlier-stage cancer uptake.
  • + Positive TroFuse-005 results showed sac-TMT improved overall survival and progression-free survival versus chemotherapy in certain endometrial cancer patients.
  • + FDA approved Lipfendra, the first and only once-daily oral PCSK9 inhibitor to reduce LDL-C in adults with hypercholesterolemia.
Bearish
  • − Non-GAAP loss per share was $0.13, driven by a $2.31 per share charge for the Terns acquisition.
  • − Full-year non-GAAP EPS guidance includes one-time charges of $3.62 per share for Cidara and $2.31 per share for Terns.
  • − Non-GAAP gross margin fell 1.1 percentage points to 81.1%, mainly on higher inventory reserves.
  • − JANUVIA/JANUMET sales fell 31% to $429 million on competition and lower demand.
  • − Total U.S. Keytruda growth is expected to moderate, and about $250 million of Q3 2025 wholesaler timing will not repeat.
  • − Third-quarter sales will be affected by the unwind of second-quarter specialty pharmacy purchases.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +3%
above
Price vs 50-day avg −9%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 62%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −10%
trailing
6-month return +15%
trailing
YTD return +26%
this year
Relative strength +21%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $145 › 200d $129 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +266 funds added
Insider flow Distributing
Net -$8.6M over 90 days · 100% sells
Short interest Falling
1.08% of shares out · ▼ -0.8% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
3,984 holders — near 3-yr high, broad support
Squeeze score 41
elevated · 0–100
Fundamentals
Strong
Revenue growth +1%
Y/Y
EPS growth +8%
Y/Y
Free cash flow $12.4B
Valuation P/E 136.9
rich
Buyback $5.7B
remaining
Balance sheet $34.8B
net debt
Quant / Vol
risk profile
Moderate
Volatility 30%
annualized · 1-yr
Max drawdown −15%
past year
ATR 3.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 8
Latest guidance · from the 8-K filed Oct 29, 2026
Sales · Full Year 2026 Raised $66.8B – $67.3B
Aug 4, 2026 $66.3B – $67.3B changed to Oct 29, 2026 $66.8B – $67.3B
prior FY $65.01B midpoint +3.1% Y/Y
Non-GAAP Gross margin · Full Year 2026 Non-GAAP Maintained 81%
Aug 4, 2026 81% changed to Oct 29, 2026 81%
Non-GAAP Operating expenses · Full Year 2026 Non-GAAP Raised $42.4B – $42.9B
Aug 4, 2026 $42B – $42.7B changed to Oct 29, 2026 $42.4B – $42.9B
Non-GAAP Other (income) expense, net · Full Year 2026 Non-GAAP Maintained $1.4B
Aug 4, 2026 $1.4B changed to Oct 29, 2026 $1.4B
Non-GAAP Effective income tax rate · Full Year 2026 Non-GAAP Lowered 32% – 33%
Aug 4, 2026 35% – 36% changed to Oct 29, 2026 32% – 33%
Non-GAAP EPS · Full Year 2026 Non-GAAP Raised $2.77 – $2.82
Aug 4, 2026 $2.66 – $2.76 changed to Oct 29, 2026 $2.77 – $2.82
Previous outlook earlier release · from the 8-K filed Feb 3, 2026

Still-open targets the latest release did not restate under the same label.

Non-GAAP Effective tax rate · Full Year 2026 23.5% – 24.5%
Guided vs delivered · last 8 settled
Sales Full Year 2025
guided $64.5B – $65B
$65.01B Beat +0.4%
Worldwide Sales Full Year 2024
guided $62.7B – $64.2B
$64.17B In line
Worldwide sales Full Year 2023
guided $59.7B – $60.2B
$60.12B In line
GAAP EPS Full-Year 2023
guided $5.85 – $5.97
$0.14 Miss −97.6%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+3% Bullish
Price vs 50-day avg
−9% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
62% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $145 › 200d $129 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +266 funds added
Insider flow Distributing
Net -$8.6M over 90 days · 100% sells
Short interest Falling
1.08% of shares out · ▼ -0.8% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
3,984 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $95 Now $133 · 62% Range high $156
vs 200-day avg +3% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Alliance Revenue - Koselugo $10M the three months ended June 30, 2026 filing —
International sales $7.24B the three months ended June 30, 2026 filing —
M-M-R II sales $96M the three months ended June 30, 2026 filing —
Non-GAAP EPS assuming dilution non-GAAP -$0.13 the three months ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
GAAP EPS assuming dilution as reported under GAAP -$0.54
+$0.41 EPS difference
= Non-GAAP EPS assuming dilution -$0.13
Non-GAAP income (loss) before taxes non-GAAP $550M the three months ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
GAAP (Loss) income before taxes as reported under GAAP -$683M
+$1.09B Acquisition- and divestiture-related costs
+$334M Restructuring costs
-$191M Income from investments in equity securities, net
= Non-GAAP income (loss) before taxes $550M
Non-GAAP net (loss) income attributable to Merck & Co., Inc. non-GAAP -$330M the three months ended June 30, 2026 filing —
ProQuad sales $235M the three months ended June 30, 2026 filing —
U.S. sales $9.37B the three months ended June 30, 2026 filing —
Varivax sales $260M the three months ended June 30, 2026 filing —
Animal Health Sales 1.8B the second quarter of 2026 —
BRAVECTO line of products sales 359M the second quarter of 2026 —
BRIDION 497M the second quarter of 2026 —
Gross margin 73.5% the second quarter of 2026 —
JANUVIA/JANUMET 429M the second quarter of 2026 —
KEYTRUDA/KEYTRUDA QLEX Sales 8.4B the second quarter of 2026 —
LAGEVRIO 5M the second quarter of 2026 —
Non-GAAP effective income tax rate non-GAAP 160.3% the second quarter of 2026 —
Non-GAAP gross margin non-GAAP 81.1% the second quarter of 2026 —
Non-GAAP net (loss) income non-GAAP -$330M Second Quarter 2026 —
Other Revenues related to the receipt of milestone payments for out-licensed products $132M June YTD 2026 —
PREVYMIS 295M the second quarter of 2026 —
PROQUAD, M-M-R II and VARIVAX 592M the second quarter of 2026 —
total alliance revenue for Koselugo $171M June YTD 2026 —
Total Vaccines sales $4.68B June YTD 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MRK
Merck & Co., Inc.
this stock
$327.41B +26.2% +1.3% 136.9 1.1%
LLY
ELI LILLY & Co
$1.27T +25.7% +44.7% 43.9 0.8%
JNJ
Johnson & Johnson
$643.09B +29.1% +6.0% 40.6 0.7%
ABBV
AbbVie Inc.
$501.19B +24.1% +8.6% 48.8 0.9%
NVS
Novartis AG
$285.60B +9.7% — — 0.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
3,984
% held
78.1%
Net QoQ
-54.6M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,636
View
Short & Settlement
Short Interest Falling
Shares short
26.6M
Days to cover
2.4d
Change
-220.9K sh
View
Short Volume
Short vol %
43%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
800
Value
$116.8K
As of
Oct 19, 2026
View
Off-Exchange
Off-exchange %
42.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$8.6M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Maria Elvira Salazar
Amount
$1.0K–$15.0K
Traded
Sep 24, 2026
View
Financials
Financials
Revenue (FY)
$65.0B
Net income (FY)
$18.3B
EPS diluted
$7.28
View
Buybacks
Authorized
$10.0B
Remaining
$5.7B
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 19, 2026
This year
27

Merck said the FDA wants trial data that include U.S. patients, after the Harmony CRL. Executives said the maturity of U.S. data matters more than the percentage of U.S. patients. They also described MK1084 as well tolerated.

View
Proposed Sales
Value
$8.6M
Shares
58.2K
Filed
Nov 12, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Feb 2, 2027
Last webcast
Nov 19, 2026
View
Investor Relations
Latest news
Merck Receives Positive EU CHMP O…
Published
Nov 13, 2026
Upcoming events
4
View

Performance

5D 20D 120D MTD YTD
MRK -9.6% -9.8% +15.3% -11.2% +26.2%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -4.2% -3.5% +21.0% -5.9% +21.2%

Capital returns

Latest dividend
$0.85 / share · ex Sep 15, 2026
Declared · upcoming
$0.88 / share · ex Dec 15, 2026
Raised 4.9%
Paid (TTM)
$3.40 / share · 4 payouts
Dividend yield (TTM, derived)
2.56%
Full dividend history
Buyback program · as of Jun 30, 2026
Authorized
$10.00B
Spent (derived)
$4.30B
Remaining
$5.70B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 310158 CUSIP 58933Y105 13F (30d) 3374 filings 3185 filers Visit website Investor relations